课题基金 / 基金详情

Identification of Transmission blocking epitopes on P. vivax 48/45 protein

Identification of Transmission blocking epitopes on P. vivax 48/45 protein
间日疟原虫 48/45 蛋白上传播阻断表位的鉴定
批准号:
8986156
负责人:
Nirbhay Kumar
金额:
$7.53万
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-12-15 至 2018-11-30

项目摘要

项目成果

Nirbhay Kumar的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Pfs48/45, a protein important for male gamete fertility, is in advanced stages of development as a Plasmodium falciparum transmission blocking vaccine. The Plasmodium vivax counterpart Pvs 48/45 is likewise expected to be an important vaccine candidate. In spite of significant sequence identify and presumed conserved biological function not much is known about the transmission blocking efficacy of antibodies against Pvs48/45 and if it will be similar to functional antibodies against Pfs48/45 as no cross-blocking reactivity has been observed. Several impediments to developing a transmission blocking vaccine for P. vivax malaria have delayed progress for this long term goal. These have included availability of conformationally suitable recombinant protein, lack of an in vivo challenge model and the inability to produce P. vivax gametocytes in the lab to test biological function of antibodies. In this application, we propose to develop certain much needed reagents to move the field forward capitalizing on success with Pfs48/45 in the co-investigator's lab. In Aim 1 we propose to generate monoclonal antibodies directed against Pvs48/45 and characterize their binding parameters and functionality through in vitro membrane feeding assays. Aim 2 will focus on examining the polymorphisms of Pvs48/45 in natural isolates and identification of epitopes recognized by antibodies elicited by natural infection. The third aim will determine the functional domains in Pvs48/45 using fragments of the protein to identify protein domains involved in forming conformational epitopes of relevance to transmission. The development of the mAb reagents against Pvs48/45 will greatly aid in understanding the biology of the protein and assist in the development of a transmission blocking vaccine based on Pvs48/45 for P. vivax malaria. While the objectives of the proposed work may appear routine, the generation of these reagents and characterization of epitopes are critical for more significant gains as discussed above as well as use of mAbs with transmission blocking potential in developing and establishing a murine model based on transgenic parasites (which is outside the scope of this application).
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1128/mbio.01627-18
发表时间: 2018-09-04
期刊: mBio
影响因子: 6.4
作者: [Cao Y, Hart RJ, Bansal GP, Kumar N]
通讯作者: Kumar N
Combination Vaccines to Interrupt Malaria Transmission
  • 批准号:
    9750618
  • 项目类别:
  • 资助金额:
    $52.71万
  • 财政年份:
    2017
  • 负责人:
    Nirbhay Kumar
  • 依托单位:
Combination Vaccines to Interrupt Malaria Transmission
  • 批准号:
    9381629
  • 项目类别:
  • 资助金额:
    $58.19万
  • 财政年份:
    2017
  • 负责人:
    Nirbhay Kumar
  • 依托单位:
Rational Approach to Optimize Immune Potency of DNA Vaccines
  • 批准号:
    8676649
  • 项目类别:
  • 资助金额:
    $18.81万
  • 财政年份:
    2013
  • 负责人:
    Nirbhay Kumar
  • 依托单位:
Rational Approach to Optimize Immune Potency of DNA Vaccines
  • 批准号:
    8535062
  • 项目类别:
  • 资助金额:
    $20.51万
  • 财政年份:
    2013
  • 负责人:
    Nirbhay Kumar
  • 依托单位:
海外基金